The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcome of concurrent treatment with a-CTLA4 and metronidazole in murine model of colon adenocarcinoma.
 
Yusra B. MEDIK
No Relationships to Disclose
 
Yifan Zhou
No Relationships to Disclose
 
Laura M. Kahn
No Relationships to Disclose
 
Bhakti Patel
No Relationships to Disclose
 
Rachel L. Babcock
No Relationships to Disclose
 
Taylor T. Chrisikos
No Relationships to Disclose
 
Xianxiu Wan
No Relationships to Disclose
 
Allison Dyevoich
No Relationships to Disclose
 
Nadim J. Ajami
No Relationships to Disclose
 
Jennifer Ann Wargo
Leadership - Microbiome DX
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; Dava Oncology; Genentech; Gilead Sciences; GlaxoSmithKline; Illumina; Merck; Novartis; Society for Immunotherapy of Cancer
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Illumina; Merck; Novartis
Speakers' Bureau - Dava Oncology; Genentech; Illumina; Novartis; PER; Precision Health Economics; Precision Health Economics
Research Funding - Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Patent submitted regarding the role of the microbiome in response to immune checkpoint blockade
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Dava Oncology; Genentech; GlaxoSmithKline; Illumina; Novartis
 
Stephanie S. Watowich
No Relationships to Disclose